These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34569969)

  • 21. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy.
    Scaglioni D; Catapano F; Ellis M; Torelli S; Chambers D; Feng L; Beck M; Sewry C; Monforte M; Harriman S; Koenig E; Malhotra J; Popplewell L; Guglieri M; Straub V; Mercuri E; Servais L; Phadke R; Morgan J; Muntoni F
    Acta Neuropathol Commun; 2021 Jan; 9(1):7. PubMed ID: 33407808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.
    Yin H; Lu Q; Wood M
    Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapy.
    Czifrus E; Berlau DJ
    Expert Rev Neurother; 2023; 23(10):853-858. PubMed ID: 37572081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.
    Yokota T; Hoffman E; Takeda S
    Methods Mol Biol; 2011; 709():299-312. PubMed ID: 21194037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
    Hiller M; Spitali P; Datson N; Aartsma-Rus A
    Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
    Cao L; Han G; Gu B; Yin H
    PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice.
    Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H
    PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
    Malerba A; Thorogood FC; Dickson G; Graham IR
    Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.
    Verhaart IE; Heemskerk H; Karnaoukh TG; Kolfschoten IG; Vroon A; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Hum Gene Ther; 2012 Mar; 23(3):262-73. PubMed ID: 22017442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.
    Sharp PS; Bye-a-Jee H; Wells DJ
    Mol Ther; 2011 Jan; 19(1):165-71. PubMed ID: 20924363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy.
    Kemaladewi DU; Hoogaars WM; van Heiningen SH; Terlouw S; de Gorter DJ; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; ten Dijke P; 't Hoen PA
    BMC Med Genomics; 2011 Apr; 4():36. PubMed ID: 21507246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
    Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
    Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon.
    Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M
    Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
    Aoki Y; Yokota T; Nagata T; Nakamura A; Tanihata J; Saito T; Duguez SM; Nagaraju K; Hoffman EP; Partridge T; Takeda S
    Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13763-8. PubMed ID: 22869723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
    Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
    Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.